HOYER OUT: Maryland Rep. Steny Hoyer will announce his retirement from Congress today, POLITICO’s Nick Wu scooped last night, ...

The offseason between the 2025 and 2026 SuperMotocross World Championship seasons was a hectic one. A host of competitors ...

Its lineup and pipeline put it well ahead of even its closest competitor. The drugmaker should continue riding this wave for the foreseeable future. Furthermore, Novo Nordisk is anticipating ...

The Washington Nationals shocked everyone when they picked Eli Willits No. 1 in the 2025 draft. Long connected to Ethan Holliday and then later breakout collegiate pitcher Kade Anderson, the fact they ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Eli Lilly’s ...

… but our independent journalism isn’t free to produce. Help us keep it this way with a tax-deductible donation today. At some point during her writing workshops, Jennifer Eli Bowen tells her students ...

Patients on Eli Lilly’s next-generation obesity shot lost nearly 30% of their body weight on average in a trial that tracked them for a little more than a year—a result that’s far better than the most ...

Eli Lilly and Company announced Tuesday it was investing more than $6 billion in a new manufacturing facility in Huntsville, Alabama. The next-generation synthetic medicine active pharmaceutical ...

Dec 1 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Monday it has lowered the price of single-dose vials of its popular obesity drug Zepbound to make the treatment more affordable for U.S.

Eli Lilly delivered 54% revenue growth in Q3 2025, raised full-year guidance, and remains a defensive haven amid market volatility. LLY's obesity and diabetes franchise, led by Zepbound, Mounjaro, and ...

The 150-year-old drugmaker is the first company in health care to hit the milestone. By Rebecca Robbins Eli Lilly, the maker of hugely popular weight loss drugs, has reached $1 trillion in value, ...

Worth another look... Although published in 2012, this remains a definitive read on leadership, management and disciplined capital allocation. In an era defined by volatility, technological disruption ...